齐拉西酮对首发精神分裂症患者的疗效及认知功能的影响

The efficacy and effects of cognitive function of Ziprasidone in the treatment of first episode schizophrenia

目的:探讨齐拉西酮对首发精神分裂症患者的疗效和对患者认知功能的影响。方法:本研究采用自身对照研究设计。对76例符合《中国精神障碍分类与诊断标准》的首发精神分裂症患者使用齐拉西酮治疗8周,于治疗前及治疗后使用阳性和阴性症状量表(PANSS)、韦氏记忆量表(WMS)和威斯康星卡片分类测验(WCST)进行评估,观察齐拉西酮对首发精神分裂症患者认知功能的影响。结果:治疗8周后,PANSS总分显著降低[(40.58±11.76)、(73.25±12.15),P<0.01];WCST中错误应答数、非持续性错误的分值显著降低(P<0.05);WMS中记忆商(MQ)、再生和理解的分值显著升高(P<0.05)。结论:齐拉西酮对首发精神分裂症患者有明确疗效,并可改善患者的部分认知功能。

Objective：To investigate the efficacy and effects of cognitive function of Ziprasidone in the treatment of first episode schizophrenia. Methods： The study adopted self - control design. 76 First episode schizophrenia patients who accorded with the diagnostic criteria of mental disorders of China took Ziprasidone for 8 weeks. The Positive and Negative Syndrome Scale （PANSS）, Wechsler Memory Scale （WMS） and Wisconsin Card Sorting Test （WCST） were used to evaluate the effects of cognitive function of first episode schizophrenia before and after the treatment. Results：After 8 weeks of treatment, the score of PANSS was decreased significantly [ （43.12 ± 13.83 ） vs. （77.68 ± 12.14 ）, P 〈 0.01 ]. The scores of fault answer and un - durative fault in WCST decreased significantly （ P 〈 0.05 ）. The memory quotient （MQ）, scores of reactive and comprehension in WMS rose significantly （ P 〈 0. 05 ）. Conclusion： Ziprasidone is effective in the treatment of first episode schizophrenia, and it can improve some patients＇ cognitive function.